CN102125524B - Piracetam orally disintegrating tablets - Google Patents
Piracetam orally disintegrating tablets Download PDFInfo
- Publication number
- CN102125524B CN102125524B CN2010100051221A CN201010005122A CN102125524B CN 102125524 B CN102125524 B CN 102125524B CN 2010100051221 A CN2010100051221 A CN 2010100051221A CN 201010005122 A CN201010005122 A CN 201010005122A CN 102125524 B CN102125524 B CN 102125524B
- Authority
- CN
- China
- Prior art keywords
- piracetam
- adjuvant
- principal agent
- oral cavity
- cavity disintegration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 229960004526 piracetam Drugs 0.000 title claims abstract description 40
- 239000006191 orally-disintegrating tablet Substances 0.000 title abstract 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 22
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 12
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 12
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 12
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 12
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 11
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229930195725 Mannitol Natural products 0.000 claims abstract description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 11
- 239000000594 mannitol Substances 0.000 claims abstract description 11
- 235000010355 mannitol Nutrition 0.000 claims abstract description 11
- 229940041616 menthol Drugs 0.000 claims abstract description 11
- 239000000741 silica gel Substances 0.000 claims abstract description 11
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 9
- 239000008101 lactose Substances 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 4
- 210000000214 mouth Anatomy 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 239000002671 adjuvant Substances 0.000 claims description 25
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 229960004543 anhydrous citric acid Drugs 0.000 claims description 10
- 229940109275 cyclamate Drugs 0.000 claims description 10
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 5
- 238000009702 powder compression Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 claims 2
- 229960001855 mannitol Drugs 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 18
- 206010039966 Senile dementia Diseases 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 15
- 238000002360 preparation method Methods 0.000 abstract description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 abstract 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 229960001866 silicon dioxide Drugs 0.000 abstract 1
- 229960001462 sodium cyclamate Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 208000004547 Hallucinations Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- -1 need not to chew Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses piracetam orally disintegrating tablets and a preparation method thereof. The main drug of the piracetam orally disintegrating tablets is piracetam, and the auxiliary materials comprise microcrystalline cellulose, mannitol, lactose, crosslinked polyvinylpyrrolidone, sodium cyclamate, menthol, silica gel micropowder and magnesium stearate. The piracetam orally disintegrating tablets can effectively treat senile dementia, have convenience in taking, good taste, rapid disintegration, quick absorption and high bioavailability, and provide convenience for patients with senile dementia who have inconvenience in taking medicine.
Description
One, technical field
The present invention relates to a kind of oral drug preparation of treating senile dementia, particularly relate to the good piracetam oral cavity disintegration tablet of a kind of disintegrate rapidly, release and mouthfeel.
Two, background technology
Piracetam is the brain metabolism improving medicine, belongs to the annular derivant of r aminobutyric acid, can promote ATP in the brain, can promote the synthetic conduction that is also just strengthening neural excitation of acetylcholine, has the effect of the brain of promotion intracellular metabolite.Can resist by the injury of brain function due to physical factor, the chemical factor, the strong prestige of the antidromicity due to the anoxia had improved action, can hypermnesis, improve learning capacity.Being used to treat senile dementia clinically, is a line medicine of treatment senile dementia.
Aging trend lets alzheimer disease patient quantity increase, and China will get into aging society, and very important problem of simultaneous---the sickness rate of senile dementia is increasing year by year.
Investigation is found: the mean age that northern China is suffered from senile dementia is 75,76 years old, and the ratio of suffering from senile dementia among the over-65s crowd reaches more than 17%.
Senile dementia patient's activity of daily living descends, and they are not familiar with spouse, children, wears the clothes, has a meal, defecation all can not take care of oneself the inconvenience of particularly taking medicine; The auditory hallucination hallucination in addition that has brings endless misery and worried for people own and on every side.Senile dementia patient's mean survival time (MST) is 5.5 years, and senile dementia has become " the fourth-largest killer " of aged health after cardiovascular diseases, cerebrovascular and cancer.
The piracetam formulation that has gone on the market abroad at present has common oral preparation and two kinds of dosage forms of injection.But many senile dementia patients all have the problem of the difficulty of taking medicine, so the ordinary tablet dosage form is used very inconvenience for the patient of the difficulty of taking medicine.Injection needs medical personnel to inject, and the patient is in and uses inconvenience.Oral cavity disintegration tablet can not need water or only need use low amounts of water, need not to chew, and tablet places lingual surface, after the rapid disintegrate of chance saliva, borrows and swallows power, and medicine can absorb onset rapidly.Compare with conventional tablet, oral cavity disintegration tablet has the following advantages: 1. absorption is fast, bioavailability is high.2. taking convenience: oral cavity disintegration tablet needn't be used water delivery service, and saliva can make its disintegrate or dissolving, can swallow by common dose, can be placed in the water again to take after the disintegrate, can also not need to take medicine with water swallow.Be particularly useful for the inconvenient senile dementia patient that takes medicine.3. intestinal is residual few, and the low medicine of side effect arrives the gastrointestinal tract rapid disintegrate of ability before and is dispersed into trickle granule, causes medicine to distribute in the gastrointestinal tract large tracts of land, and absorption point increases, thereby has reduced medicine to the gastrointestinal local excitation.4. avoid the first pass effect of liver: because oral cavity disintegration tablet rapidly disintegrate in mouth except that major part gets into the gastrointestinal tract with swallowing act, also has the considerable part trans-oral to absorb, thereby rapid-action, first pass effect is little.
Oral cavity disintegration tablet develops by its distinct feature rapidly, becomes the emphasis of tablet exploitation.Oral cavity disintegration tablet is applicable to old people and child's oral medication, especially for the patient of dysphagia, has more suitable use advantage, thereby has found a kind of way of solution for the quality of life of improving patient.
Three, summary of the invention
The object of the present invention is to provide a kind of taking convenience, mouthfeel is good, and disintegrate is rapid, absorbs fast piracetam oral cavity disintegration tablet and preparation method thereof.
The object of the invention can be realized through following measure:
The piracetam oral cavity disintegration tablet comprises principal agent and adjuvant, it is characterized in that principal agent and adjuvant are formulated by following percentage by weight: principal agent 15%-33%, adjuvant 67%-85%.
Principal agent of the present invention is a piracetam, molecular formula: C
6H
10N
2O
2, molecular weight: 140.16.
Principal agent of the present invention and adjuvant are formulated by following percentage by weight:
A. piracetam 15-33%
B. microcrystalline Cellulose 10-30%
C. mannitol 20-55%
D. lactose 10-25%
E. anhydrous citric acid 0.5-1.0%
F. crospolyvinylpyrrolidone 3-10%
G. cyclamate 0.75-2%
H. menthol 0.1-1%
I. micropowder silica gel 0.5-2.5%
J. magnesium stearate 0.2-0.9%
Wherein lactose, mannitol are filler; Microcrystalline Cellulose, crospolyvinylpyrrolidone are disintegrating agent, and wherein microcrystalline Cellulose also has lubricated and disintegration concurrently, and anhydrous citric acid, cyclamate and menthol are correctives; Micropowder silica gel is a fluidizer, and magnesium stearate is as lubricant.
2. the method for preparing of piracetam oral cavity disintegration tablet according to claim 1 comprises raw material pulverizing, weighing mixing, sheeting process.It is characterized in that, comprise following concrete processing step:
Step 1: with piracetam and various adjuvant pulverize separately, cross 40 mesh sieves then, preserve subsequent use respectively;
Step 2: take by weighing principal agent and the various adjuvant that step 1 is produced by principal agent and accessory formula, and with its abundant mix homogeneously; Step 3: the mixed uniformly material of step 2 is sent into tablet machine, carry out direct powder compression.
The invention has the advantages that:
(1) the present invention fills a prescription rationally, and each adjuvant is cheap and easy to get, and good with the principal agent compatibility, preparation technology is simple, is applicable to large-scale industrial production;
(2) the piracetam oral cavity disintegration tablet disintegrate that the present invention relates to is rapid, mouthfeel good, and the no grittiness that enters the mouth and cool taste do not have other uncomfortable taste yet;
(3) piracetam oral cavity disintegration tablet taking convenience of the present invention can effectively be treated senile dementia.Convenience is provided for the senile dementia patient of the inconvenience of taking medicine.
Below in conjunction with specific embodiment the present invention is further described.
The specific embodiment
Embodiment 1
The piracetam oral cavity disintegration tablet comprises principal agent and adjuvant, it is characterized in that by following percentage by weight formulated: principal agent 25%, adjuvant 75%.
Piracetam 100g (25%)
Microcrystalline Cellulose 75g (18.75%)
Mannitol 120g (30%)
Lactose 78g (19.5%)
Anhydrous citric acid 2.25g (0.56%)
Crospolyvinylpyrrolidone 11.25g (2.81%)
Cyclamate 4.5g (1.13%)
Menthol 3.75g (0.94%)
Micropowder silica gel 3.75g (0.94%)
Magnesium stearate 1.5g (0.37%)
Make 1000 altogether
Wherein lactose, mannitol are filler, and microcrystalline Cellulose, crospolyvinylpyrrolidone are disintegrating agent, and anhydrous citric acid, cyclamate and menthol are correctives, and magnesium stearate is a lubricant, and micropowder silica gel is a fluidizer.
The method for preparing of piracetam oral cavity disintegration tablet of the present invention comprises raw material pulverizing, weighing mixing, sheeting process.It is characterized in that concrete processing step is following:
Step 1: with piracetam and various adjuvant pulverize separately, cross 40 mesh sieves then, preserve subsequent use respectively;
Step 2: take by weighing principal agent and the various adjuvant that step 1 is produced by principal agent and accessory formula, and with its abundant mix homogeneously;
Step 3: the component that step 2 mixes is sent into conventional tablet machine, carry out direct powder compression, make sheet and heavily be the piracetam oral cavity disintegration tablet of 400mg.
Result of the test:
Tablet hardness: 33 ± 5N
Disintegration: 19～28s
Disintegrate in intraoral disintegration time limit and mouthfeel: the 40S, no grittiness, cool taste does not have uncomfortable taste embodiment 2
The piracetam oral cavity disintegration tablet comprises principal agent and adjuvant, it is characterized in that by following percentage by weight formulated: principal agent 31.25%, adjuvant 68.75%.
Piracetam 125g (31.25%)
Microcrystalline Cellulose 50g (12.5%)
Mannitol 150g (37.5%)
Lactose 45g (11.25%)
Anhydrous citric acid 2.25g (0.56%)
Crospolyvinylpyrrolidone 15g (3.75%)
Cyclamate 3g (0.75%)
Menthol 3g (0.75%)
Micropowder silica gel 4.5g (1.13%)
Magnesium stearate 2.25g (0.56%)
Make 1000 altogether
Pyrrole of the present invention draws the method for preparing of two smooth oral cavity disintegration tablets with embodiment 1, makes sheet and heavily is the piracetam oral cavity disintegration tablet of 400mg.
Result of the test:
Tablet hardness: 32 ± 5N
Disintegration: 14～27s
Disintegrate in intraoral disintegration time limit and mouthfeel: the 40S, no grittiness, cool taste does not have uncomfortable taste
Embodiment 3
The piracetam oral cavity disintegration tablet comprises principal agent and adjuvant, it is characterized in that by following percentage by weight formulated: principal agent 18.75%, adjuvant 81.25%.
Piracetam 75g (18.75%)
Microcrystalline Cellulose 105g (26.25%)
Mannitol 100.25g (25.06%)
Lactose 84.875g (21.22%)
Anhydrous citric acid 3g (0.75%)
Crospolyvinylpyrrolidone 18.75g (4.69%)
Cyclamate 3.75g (0.94%)
Menthol 0.375g (0.094%)
Micropowder silica gel 6g (1.5%)
Magnesium stearate 3g (0.75%)
Make 1000 altogether
The method for preparing of piracetam oral cavity disintegration tablet of the present invention makes sheet and heavily is the piracetam oral cavity disintegration tablet of 400mg with embodiment 1.
Result of the test:
Tablet hardness: 36 ± 5N
Disintegration: 19～33s
Disintegrate in intraoral disintegration time limit and mouthfeel: the 40S, no grittiness, cool taste does not have uncomfortable taste.
The piracetam oral cavity disintegration tablet disintegrate that the present invention relates to is rapid, mouthfeel good, and the no grittiness that enters the mouth and cool taste do not have other uncomfortable taste yet; Can effectively treat senile dementia, convenience is provided for the senile dementia patient of the inconvenience of taking medicine.
Claims (2)
1. piracetam oral cavity disintegration tablet; Comprise principal agent and adjuvant; It is characterized in that principal agent is a piracetam, adjuvant is microcrystalline Cellulose, mannitol, lactose, anhydrous citric acid, crospolyvinylpyrrolidone, cyclamate, menthol, micropowder silica gel, magnesium stearate; Described principal agent and adjuvant are prepared by following quality:
Piracetam 100g, microcrystalline Cellulose 75g, mannitol 120g, lactose 78g, anhydrous citric acid 2.25g, crospolyvinylpyrrolidone, 11.25g, cyclamate 4.5g, menthol 3.75g, micropowder silica gel 3.75g, magnesium stearate 1.5 g make 1000;
The method for preparing of said piracetam oral cavity disintegration tablet comprises raw material pulverizing, weighing mixing, sheeting process, and concrete processing step is following:
Step 1: with piracetam and various adjuvant pulverize separately, cross 40 mesh sieves then, preserve subsequent use respectively;
Step 2: take by weighing principal agent and the various adjuvant that step 1 is produced by principal agent and accessory formula, and with its abundant mix homogeneously;
Step 3: the mixed uniformly material of step 2 is sent into tablet machine, carry out direct powder compression.
2. piracetam oral cavity disintegration tablet; Comprise principal agent and adjuvant; It is characterized in that principal agent is a piracetam, adjuvant is microcrystalline Cellulose, mannitol, lactose, anhydrous citric acid, crospolyvinylpyrrolidone, cyclamate, menthol, micropowder silica gel, magnesium stearate; Described principal agent and adjuvant are prepared by following quality:
Piracetam 125g, microcrystalline Cellulose 50g, mannitol 150g, lactose 45g, anhydrous citric acid 2.25g, crospolyvinylpyrrolidone 15g, cyclamate 3g, menthol 3g, micropowder silica gel 4.5g, magnesium stearate 2.25 g make 1000;
The method for preparing of said piracetam oral cavity disintegration tablet comprises raw material pulverizing, weighing mixing, sheeting process, and concrete processing step is following:
Step 1: with piracetam and various adjuvant pulverize separately, cross 40 mesh sieves then, preserve subsequent use respectively;
Step 2: take by weighing principal agent and the various adjuvant that step 1 is produced by principal agent and accessory formula, and with its abundant mix homogeneously;
Step 3: the mixed uniformly material of step 2 is sent into tablet machine, carry out direct powder compression.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010100051221A CN102125524B (en) | 2010-01-16 | 2010-01-16 | Piracetam orally disintegrating tablets |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010100051221A CN102125524B (en) | 2010-01-16 | 2010-01-16 | Piracetam orally disintegrating tablets |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102125524A CN102125524A (en) | 2011-07-20 |
| CN102125524B true CN102125524B (en) | 2012-06-27 |
Family
ID=44263961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010100051221A Expired - Fee Related CN102125524B (en) | 2010-01-16 | 2010-01-16 | Piracetam orally disintegrating tablets |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102125524B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104546682A (en) * | 2014-12-25 | 2015-04-29 | 海南卫康制药(潜山)有限公司 | Piracetam composition freeze-dried tablets and preparation method thereof |
| CN106727898B (en) * | 2017-02-21 | 2020-07-31 | 阮时宝 | Pharmaceutical composition for preventing and treating Alzheimer disease and preparation method thereof |
| CN111297818B (en) * | 2020-04-02 | 2022-02-22 | 常州制药厂有限公司 | High-drug-loading-capacity piracetam tablet composition and preparation method thereof |
| CN112022816B (en) * | 2020-07-31 | 2022-08-12 | 河北君临药业有限公司 | Piracetam tablet and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1663563A (en) * | 2005-02-04 | 2005-09-07 | 北京阜康仁生物制药科技有限公司 | Compound troxerutin and piracetam formulation and application thereof |
| CN101274013A (en) * | 2007-03-27 | 2008-10-01 | 高海 | Prescription medicine for curing senile dementia and preparation |
-
2010
- 2010-01-16 CN CN2010100051221A patent/CN102125524B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1663563A (en) * | 2005-02-04 | 2005-09-07 | 北京阜康仁生物制药科技有限公司 | Compound troxerutin and piracetam formulation and application thereof |
| CN101274013A (en) * | 2007-03-27 | 2008-10-01 | 高海 | Prescription medicine for curing senile dementia and preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102125524A (en) | 2011-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8329744B2 (en) | Methods of preventing the serotonin syndrome and compositions for use thereof | |
| CA2332253A1 (en) | Combination therapy for treatment of depression | |
| JP5864819B2 (en) | Pharmaceutical composition for the prevention and treatment of mental disorders, behavioral disorders and cognitive disorders | |
| CN102125524B (en) | Piracetam orally disintegrating tablets | |
| KR101562608B1 (en) | Compound chemical medicine acting on respiratory disease, preparation process and use thereof | |
| CN102631331A (en) | Olanzapine oral disintegration tablet and preparation method thereof | |
| CN104510717B (en) | Olanzapine orally-disintegrating tablet and preparation method thereof | |
| CN102125525B (en) | Orally disintegrating tablet with rivastigmine tartrate | |
| CN108261399A (en) | Olanzapine oral disnitegration tablet and preparation method thereof | |
| JP3884056B1 (en) | Method for producing intraoral rapidly disintegrating tablet | |
| CN106137988A (en) | A kind of metronidazole solid preparation and preparation method thereof | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CN102100676B (en) | Vinpocetine orally disintegrating tablets | |
| CN103040780A (en) | Rapidly disintegrating pramipexole tablet drug composition and preparation method thereof | |
| CN107108560A (en) | Compound, composition and its method | |
| CN105476967A (en) | Blonanserin pharmaceutical composition and preparation method thereof | |
| CN101797244B (en) | Levodopa/benserazide orally disintegrating tablet | |
| CN101152157A (en) | Meloxicam orally disintegrating tablets and method for preparing the same | |
| CN100571687C (en) | A kind of double sodium valproate orally disintegrating tablets and preparation method thereof | |
| CN1931140A (en) | Orally disintegrated galantamine hydrobromide tablet and its prepn process | |
| Prajapati et al. | Formulation and evaluation of mouth dissolving Sublingual tablets of Cimetidine to treat abdominal cramps | |
| CN1430953A (en) | Tablet disintegzated in mouth rapidly for preventing and curing vomit and preparing method | |
| CN101766605B (en) | Pramipexole-contained pharmaceutical composition capable of being dispersed in mouth | |
| CN1250278C (en) | Oral medicine for treating dementia and feeblemindedpess | |
| KR102375872B1 (en) | Pharmaceutical composition for preventing or treating periodontal disease which has improved convenience for internal use through size reduction for formulation using iLet(innovative Low excipient tablet) technology comprising titrated extract of the unsaponifiable fraction of Zea Mays L. and extract of Magnoliae Cortex |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120627 Termination date: 20130116 |